NRx Pharmaceuticals (NRXP) Competitors $2.66 -0.06 (-2.02%) As of 02:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. GNFT, OGI, EPRX, TVGN, CTMX, ENGN, KYTX, IPHA, SXTC, and GALTShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include GENFIT (GNFT), Organigram Global (OGI), Eupraxia Pharmaceuticals (EPRX), Semper Paratus Acquisition (TVGN), CytomX Therapeutics (CTMX), enGene (ENGN), Kyverna Therapeutics (KYTX), Innate Pharma (IPHA), China SXT Pharmaceuticals (SXTC), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors GENFIT Organigram Global Eupraxia Pharmaceuticals Semper Paratus Acquisition CytomX Therapeutics enGene Kyverna Therapeutics Innate Pharma China SXT Pharmaceuticals Galectin Therapeutics NRx Pharmaceuticals (NASDAQ:NRXP) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Do analysts rate NRXP or GNFT? NRx Pharmaceuticals presently has a consensus price target of $28.50, indicating a potential upside of 969.42%. GENFIT has a consensus price target of $13.00, indicating a potential upside of 227.46%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in NRXP or GNFT? 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of GENFIT shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, NRXP or GNFT? NRx Pharmaceuticals has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Is NRXP or GNFT more profitable? Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -355.00% GENFIT N/A N/A N/A Which has better earnings and valuation, NRXP or GNFT? GENFIT has higher revenue and earnings than NRx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$25.13M-$2.01-1.33GENFIT$76.77M2.59$1.63MN/AN/A Does the media prefer NRXP or GNFT? In the previous week, NRx Pharmaceuticals had 2 more articles in the media than GENFIT. MarketBeat recorded 3 mentions for NRx Pharmaceuticals and 1 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat NRx Pharmaceuticals' score of -0.09 indicating that GENFIT is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GENFIT 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNRx Pharmaceuticals beats GENFIT on 8 of the 12 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.08M$2.51B$5.54B$9.49BDividend YieldN/A1.78%4.73%4.14%P/E Ratio-1.338.9529.0424.35Price / SalesN/A444.15374.0878.76Price / CashN/A22.2824.4827.20Price / Book-1.804.998.645.82Net Income-$25.13M$31.61M$3.24B$264.73M7 Day Performance-7.47%-1.91%0.22%-0.99%1 Month Performance-19.49%5.72%7.96%6.06%1 Year Performance32.59%5.29%29.96%23.79% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals2.7419 of 5 stars$2.67-2.0%$28.50+969.4%+28.3%$46.08MN/A-1.332News CoverageAnalyst ForecastGap UpGNFTGENFIT1.7747 of 5 stars$4.16+0.5%$13.00+212.5%-5.7%$207.01M$76.77M0.00120OGIOrganigram Global1.2506 of 5 stars$1.48-3.3%N/A-7.4%$204.93M$117.47M14.80860EPRXEupraxia Pharmaceuticals2.8033 of 5 stars$5.64+2.7%$11.00+95.2%+108.8%$197.40MN/A-7.4229Upcoming EarningsHigh Trading VolumeTVGNSemper Paratus Acquisition3.5082 of 5 stars$1.08+1.9%$10.00+825.9%+76.9%$194.93MN/A0.003News CoverageAnalyst ForecastCTMXCytomX Therapeutics4.0037 of 5 stars$2.39-0.4%$5.33+123.2%+82.4%$193.49M$138.10M4.98170Upcoming EarningsENGNenGene3.4931 of 5 stars$3.64-1.6%$23.29+539.7%-54.4%$189.09MN/A-2.2131KYTXKyverna Therapeutics2.6789 of 5 stars$4.33flat$18.50+327.3%-53.5%$187.14MN/A-1.2896News CoverageUpcoming EarningsIPHAInnate Pharma2.9292 of 5 stars$2.20+8.4%$11.00+400.0%-1.6%$187.13M$12.62M0.00220Positive NewsGap UpHigh Trading VolumeSXTCChina SXT Pharmaceuticals0.7442 of 5 stars$1.56-1.9%N/A-81.5%$184.48M$1.93M0.0090News CoveragePositive NewsAnalyst UpgradeGALTGalectin Therapeutics2.7115 of 5 stars$3.06+5.2%$6.00+96.1%+62.1%$184.18MN/A-4.259News CoverageUpcoming Earnings Related Companies and Tools Related Companies GENFIT Alternatives Organigram Global Alternatives Eupraxia Pharmaceuticals Alternatives Semper Paratus Acquisition Alternatives CytomX Therapeutics Alternatives enGene Alternatives Kyverna Therapeutics Alternatives Innate Pharma Alternatives China SXT Pharmaceuticals Alternatives Galectin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
